RxDoctor Payments Data

Chrishana Ogilvie, MD

Allergy · Germantown, TNNPI 1225256613

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 42.7% of the total. 2025 is the largest year on record at $601, 4.7 times the $127 reported in 2019.

$2,393in general payments, 2019–2025

Across 87 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$315
  • GSK$226
  • Genentech USA, Inc.$184
  • Sanofi$181
  • Kaleo, Inc.$145
  • plus $320 from 11 others

What the payments were for

  • Food & beverage$2,35999%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,425
Medicare patients
70
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab20$93,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,668
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,098
Azelastine Hcl22$1,154
Albuterol Sulfate HfaAlbuterol Sulfate16$285
Famotidine12$191
Fluticasone Propionate14$171
Montelukast Sodium28$159
Prednisone11$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$226$22,66831 claims
AstraZenecaBreztri Aerosphere$1,023$8,09813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other allergy in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →